The Caliciviridae is a family of positive-strand RNA viruses and consists of five genera designated: (1) Norovirus (with species Norwalk virus);(2) Sapovirus (with species Sapporo virus);(3) Vesivirus (with species, feline calicivirus and vesicular exanthema of swine virus);(4) Lagovirus (with species rabbit hemorrhagic disease virus and European brown hare syndrome virus) and (5) Nebovirus (with species Newbury-2 virus). The Caliciviruses Section in LID is focused on one major goal: lessen the disease burden from caliciviruses that cause disease in humans. Noroviruses are the primary focus of our research because they are the major calicivirus pathogens in humans. They cause the majority of epidemic gastroenteritis outbreaks and are second to rotaviruses as agents of severe diarrhea in infants and young children. They can cause chronic infection and life-threatening illness in immunocompromised individuals. Noroviruses are genetically-diverse and most human norovirus pathogens belong to either Genogroup I (GI) or Genogroup II (GII), with GII.4 as the predominant genotype. Because a major technical challenge in the study of these viruses is the inability to grow them in cultured cells, our laboratory has developed calicivirus replication systems and animal models to establish parameters of infection and immunity. This year we investigated the mini pig as an animal model in which to evaluate norovirus vaccines and therapeutic drugs. We continued our collaboration with a leading company in norovirus vaccine development, Takeda Vaccines Montana (formerly LigoCyte Pharmaceuticals, Inc.), to address the immunogenicity and broad reactivity of new norovirus vaccine candidates. One approach under consideration for the treatment of norovirus disease is therapeutic antibodies, and we have made progress in this area. In collaboration with Dr. Robert H. Purcell (LID), we generated the first norovirus-specific antibodies with putative neutralizing activity as demonstrated in the chimpanzee model before the model was discontinued. We are continuing to develop and map additional antibodies in the laboratory, generated by a variety of technologies including nanobody technology in collaboration with Dr. Viviana Parreo at INTA in Argentina. One goal is to map cross-reactive antigenic sites that might serve as targets for the design of broadly-protective vaccines. Two patents were filed this year for the unique antibodies generated in these projects, and studies are planned to evaluate their efficacy. This will be facilitated by the addition to our team this year of a gastroenterology medical fellow and an experienced postdoctoral fellow who will work together to evaluate identify therapeutic approaches that could be translated to clinical evaluation.

Project Start
Project End
Budget Start
Budget End
Support Year
14
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Niaid Extramural Activities
Department
Type
DUNS #
City
State
Country
Zip Code
Santiana, Marianita; Ghosh, Sourish; Ho, Brian A et al. (2018) Vesicle-Cloaked Virus Clusters Are Optimal Units for Inter-organismal Viral Transmission. Cell Host Microbe 24:208-220.e8
Daniel-Wayman, Shelby; Fahle, Gary; Palmore, Tara et al. (2018) Norovirus, astrovirus, and sapovirus among immunocompromised patients at a tertiary care research hospital. Diagn Microbiol Infect Dis 92:143-146
Green, Kim Y (2018) Norovirus surveillance comes of age: the impact of NoroNet. Lancet Infect Dis 18:482-483
Levenson, Eric A; Martens, Craig; Kanakabandi, Kishore et al. (2018) Comparative Transcriptomic Response of Primary and Immortalized Macrophages to Murine Norovirus Infection. J Immunol 200:4157-4169
Tin, Christine M; Yuan, Lijuan; Dexter, Rachel J et al. (2017) A Luciferase Immunoprecipitation System (LIPS) assay for profiling human norovirus antibodies. J Virol Methods 248:116-129
Sosnovtsev, Stanislav V; Sandoval-Jaime, Carlos; Parra, Gabriel I et al. (2017) Identification of Human Junctional Adhesion Molecule 1 as a Functional Receptor for the Hom-1 Calicivirus on Human Cells. MBio 8:
Cotton, Ben T; Hyde, Jennifer L; Sarvestani, Soroush T et al. (2017) The Norovirus NS3 Protein Is a Dynamic Lipid- and Microtubule-Associated Protein Involved in Viral RNA Replication. J Virol 91:
Johnson, J A; Parra, G I; Levenson, E A et al. (2017) A large outbreak of acute gastroenteritis in Shippensburg, Pennsylvania, 1972 revisited: evidence for common source exposure to a recombinant GII.Pg/GII.3 norovirus. Epidemiol Infect 145:1591-1596
Sharma, Sumit; Carlsson, Beatrice; Czakó, Rita et al. (2017) Human Sera Collected between 1979 and 2010 Possess Blocking-Antibody Titers to Pandemic GII.4 Noroviruses Isolated over Three Decades. J Virol 91:
Di Martino, Barbara; Di Profio, Federica; Melegari, Irene et al. (2017) Seroprevalence for norovirus genogroup II, IV and VI in dogs. Vet Microbiol 203:68-72

Showing the most recent 10 out of 57 publications